Affymetrix Technology Helps Advance Schizophrenia Research

Affymetrix Inc. (Nasdaq:AFFX) announced today that researchers around the world have used the Affymetrix Genome-Wide Human SNP Arrays 5.0 and 6.0 to uncover important links between copy number variations (CNVs) and schizophrenia. Researchers from the United States, Europe and Asia published their findings in recent issues of Nature and Nature Genetics.

Source: Affymetrix